Investigating causes of heterogeneity in systematic reviews

被引:149
作者
Glasziou, PP
Sanders, SL
机构
[1] Univ Queensland, Ctr Evidence Based Hlth Ctr, Brisbane, Qld, Australia
[2] Univ Queensland, Ctr Gen Practice, Brisbane, Qld, Australia
关键词
heterogeneity; systematic review; meta analysis; effect modification; interaction;
D O I
10.1002/sim.1183
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
What causes heterogeneity in systematic reviews of controlled trials? First, it may be an artefact of the summary measures used, of study design features such as duration of follow-up or the reliability of outcome measures. Second, it may be due to real variation in the treatment effect and hence provides the opportunity to identify factors that may modify the impact of treatment. These factors may include features of the population such as: severity of illness, age and gender; intervention factors such as dose, timing or duration of treatment; and comparator factors such as the control group treatment or the co-interventions in both groups. The ideal way to study causes of true variation is within rather than between studies. In most situations however, we will have to make do with a study level investigation and hence need to be careful about adjusting for potential confounding by artefactual factors such as study design features. Such investigation of artefactual and true causes of heterogeneity form essential steps in moving from a combined effect estimate to application to particular populations and individuals. Copyright (C) 2002 John Wiley Sons, Ltd.
引用
收藏
页码:1503 / 1511
页数:9
相关论文
共 25 条
  • [11] METAANALYSIS ADJUSTING FOR COMPLIANCE - THE EXAMPLE OF SCREENING FOR BREAST-CANCER
    GLASZIOU, PP
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 1992, 45 (11) : 1251 - 1256
  • [12] Quantifying heterogeneity in a meta-analysis
    Higgins, JPT
    Thompson, SG
    [J]. STATISTICS IN MEDICINE, 2002, 21 (11) : 1539 - 1558
  • [13] Hunter J.E., 1990, METHODS METAANALYSIS
  • [14] LUBSEN J, 1989, CONTROL CLIN TRIALS, V10, pS151
  • [15] RODGERS A, 1995, THROMB HAEMOSTASIS, V73, P167
  • [16] Schmid CH, 1998, STAT MED, V17, P1923, DOI 10.1002/(SICI)1097-0258(19980915)17:17<1923::AID-SIM874>3.0.CO
  • [17] 2-6
  • [18] EMPIRICAL-EVIDENCE OF BIAS - DIMENSIONS OF METHODOLOGICAL QUALITY ASSOCIATED WITH ESTIMATES OF TREATMENT EFFECTS IN CONTROLLED TRIALS
    SCHULZ, KF
    CHALMERS, I
    HAYES, RJ
    ALTMAN, DG
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 273 (05): : 408 - 412
  • [19] Sharp SJ, 1996, BRIT MED J, V313, P735
  • [20] Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis - The CLASS study: A randomized controlled trial
    Silverstein, FE
    Faich, G
    Goldstein, JL
    Simon, LS
    Pincus, T
    Whelton, A
    Makuch, R
    Eisen, G
    Agarwal, NM
    Stenson, WF
    Burr, AM
    Zhao, WW
    Kent, JD
    Lefkowith, JB
    Verburg, KM
    Geis, GS
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 284 (10): : 1247 - 1255